Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Bipolar Episodes
Schizophrenia

Study type

Observational

Funder types

Industry

Identifiers

NCT01689389
NIS-NFR-SER-2012/1

Details and patient eligibility

About

The aim of the study is to describe patient characteristics (demographic and clinical) and the patterns of use of Quetiapine XR in patients receiving the drug for the first time in real-life practice regardless the final diagnosis.

Full description

Description of the use of Quetiapine Extended Release (XR) in real-life practice in France

Enrollment

2,292 patients

Sex

All

Ages

18 to 130 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • New patients treated with Xeroquel XR
  • Patients aged 18 years and over
  • Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria

Exclusion criteria

  • Patient included in a therapeutic trial (Huriet-Serusclat Act)
  • Patient refusing to participate in the study
  • Pregnant women

Trial design

2,292 participants in 3 patient groups

Main study population
Description:
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months.
Schizophrenia SoC sample
Description:
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
Bipolar SoC sample
Description:
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].

Trial contacts and locations

19

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems